Prognostic significance of blood coagulation tests in carcinoma of the lung and colon.
Blood coagulation test results were collected prospectively in patients with previously untreated, advanced lung or colon cancer who entered into a clinical trial. In patients with colon cancer, reduced survival was associated (in univariate analysis) with higher values obtained at entry to the study for fibrinogen, fibrin(ogen) split products, antiplasmin, and fibrinopeptide A and accelerated euglobulin lysis times. In patients with non-small cell lung cancer, reduced survival was associated (in univariate analysis) with higher fibrinogen and fibrin(ogen) split products, platelet counts and activated partial thromboplastin times. In patients with small cell carcinoma of the lung, only higher activated partial thromboplastin times were associated (in univariate analysis) with reduced survival in patients with disseminated disease. In multivariate analysis, higher activated partial thromboplastin times were a significant independent predictor of survival for patients with non-small cell lung cancer limited to one hemithorax and with disseminated small cell carcinoma of the lung. Fibrin(ogen) split product levels were an independent predictor of survival for patients with disseminated non-small cell lung cancer as were both the fibrinogen and fibrinopeptide A levels for patients with disseminated colon cancer. These results suggest that certain tests of blood coagulation may be indicative of prognosis in lung and colon cancer. The heterogeneity of these results suggests that the mechanism(s), intensity, and pathophysiological significance of coagulation activation in cancer may differ between tumour types.
Wojtukiewicz
M Z
MZ
Department of Medicine, Dartmouth Medical School.
Zacharski
L R
LR
Moritz
T E
TE
Hur
K
K
Edwards
R L
RL
Rickles
F R
FR
D001780:Blood Coagulation Tests; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000401:mortality; D018288:Carcinoma, Small Cell / Q000097:blood / Q000401:mortality; D003110:Colonic Neoplasms / Q000097:blood* / Q000401:mortality; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood* / Q000401:mortality; D015999:Multivariate Analysis; D010314:Partial Thromboplastin Time; D010976:Platelet Count; D011379:Prognosis; D011446:Prospective Studies
D005338:Fibrin Fibrinogen Degradation Products; D005340:Fibrinogen